Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 6/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18547101 | 0.90 | P2RX3 (0.46) | P2RX3P2RX2LMNASMN1; SMN2MAPT | |
| SCHEMBL18562613 | 0.88 | P2RX3 (0.40) | P2RX3P2RX2NPC1RAB9ALMNA | |
| SCHEMBL18547130 | 0.88 | KCNH2 (0.40) | P2RX3P2RX2NPC1RAB9ALMNA | |
| SCHEMBL18547185 | 0.88 | CNR2 (0.46) | P2RX3P2RX2NPC1RAB9ALMNA | |
| SCHEMBL18547398 | 0.87 | CNR1 (0.42) | P2RX3P2RX2CNR1 | |
| SCHEMBL18576327 | 0.85 | P2RX3 (0.38) | P2RX3P2RX2NPC1RAB9ALMNA | |
| SCHEMBL18547364 | 0.84 | JAK2 (0.44) | NPC1RAB9ALMNASMN1; SMN2MAPT | |
| SCHEMBL18547319 | 0.84 | CNR1 (0.41) | P2RX3P2RX2CNR1 | |
| SCHEMBL20679677 | 0.82 | LMNA (0.40) | NPC1RAB9ALMNASMN1; SMN2MAPT | |
| SCHEMBL18562614 | 0.81 | LMNA (0.40) | P2RX3P2RX2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | P2RX3 69/4885P2RX2 94/4885NPC1 230/4885 |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | P2RX3 70/4885P2RX2 93/4885NPC1 230/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | P2RX3 70/4885P2RX2 93/4885NPC1 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.